Prawo i regulacje · 25.11.2003

Recordkeeping and Reporting Requirements for Drug Products Containing Gamma-Hydroxybutyric Acid (GHB)

DEA proposes to amend its regulations to require additional recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB) for which an application has been approved under the Federal Food, Drug, and Cosmetic Act. DEA proposes these changes pursuant to section 4 of the "Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000." These additional requirements are necessary to protect against the diversion of GHB for illicit purposes.

Source: Federal Register — Justice DepartmentOpen original release →

Recordkeeping and Reporting Requirements for Drug Products Containing Gamma-Hydroxybutyric Acid (GHB)

Notice of Lodging of Proposed Stipulation and Order of Settlement Under the Toxic Substances Control Act

Notice of Lodging of Proposed Final Supplemental Consent Decree Under the Clean Water Act

Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.

Importer of Controlled Substances Application: Irvine Labs, Inc.

Agency Information Collection Activities; Proposed eCollection eComments Requested; Reinstatement, With Change, of a Previously Approved Collection, for Which Approval Has Expired: Title-2026 National Survey of Victim Service Providers

Craig Cohen, DPM; Decision and Order